Efficacy and safety of tocilizumab in the management of COVID-19: a systematic review and meta-analysis of observational studies

This article has been Reviewed by the following groups

Read the full article See related articles

Abstract

No abstract available

Article activity feed

  1. SciScore for 10.1101/2021.01.27.21250599: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board Statementnot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    , anti-histaminic (cetirizine,), antibiotics (cephalosporins), corticosteroids (prednisolone, methylprednisolone), monoclonal antibodies (tocilizumab, imatinib) [16].
    anti-histaminic (cetirizine,),
    suggested: None
    Software and Algorithms
    SentencesResources
    Methods: The electronic search was performed using PubMed, Scopus, CENTRAL, and Google scholar to identify the retrospective observational reports.
    PubMed
    suggested: (PubMed, RRID:SCR_004846)
    Further, the pre-print servers such as Research Square, bioRxiv.org, and medRxiv were also considered while searching the grey literature.
    bioRxiv
    suggested: (bioRxiv, RRID:SCR_003933)
    An example of a search strategy using PUBMED and Google Scholar has been highlighted in Annexure 1.
    Google Scholar
    suggested: (Google Scholar, RRID:SCR_008878)
    2.3 Quality assessment and Risk of Bias analysis for included studies All the included studies were subjected to the quality assessment using the Newcastle-Ottawa scale and also evaluated for risk of bias using the Cochrane Collaboration tool to assess The Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I). 2.4.
    Cochrane Collaboration tool
    suggested: None
    Statistical analysis Review Manager (RevMan, version 5.3; Nordic Cochrane Centre
    RevMan
    suggested: (RevMan, RRID:SCR_003581)
    [Cochrane Collaboration], Copenhagen, Denmark; 2014) shall be used to analyze the data.
    Cochrane Collaboration
    suggested: None

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: We found the following clinical trial numbers in your paper:

    IdentifierStatusTitle
    NCT04346355TerminatedEfficacy of Early Administration of Tocilizumab in COVID-19 …
    NCT04331808Active, not recruitingCORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI)
    NCT04356937CompletedEfficacy of Tocilizumab on Patients With COVID-19
    NCT04320615CompletedA Study to Evaluate the Safety and Efficacy of Tocilizumab i…
    NCT02735707RecruitingRandomized, Embedded, Multifactorial Adaptive Platform Trial…
    NCT04372186Active, not recruitingA Study to Evaluate the Efficacy and Safety of Tocilizumab i…
    NCT04317092Active, not recruitingTocilizumab in COVID-19 Pneumonia (TOCIVID-19)
    NCT04445272CompletedClinical Trial to Evaluate the Effectiveness and Safety of T…
    NCT04377659Active, not recruitingTocilizumab for Prevention of Respiratory Failure in Patient…
    NCT04330638Active, not recruitingTreatment of COVID-19 Patients With Anti-interleukin Drugs
    NCT04345445Not yet recruitingStudy to Evaluate the Efficacy and Safety of Tocilizumab Ver…
    NCT04372602RecruitingDuvelisib to Combat COVID-19
    NCT0442553810Trial number did not resolve on clinicaltrials.gov. Is the number correct?NA


    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


    Results from JetFighter: We did not find any issues relating to colormaps.


    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.